DS-1123
/ Daiichi Sankyo
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 04, 2018
Study of DS-1123a in Advanced Solid Tumours
(clinicaltrials.gov)
- P1; N=27; Completed; Sponsor: Daiichi Sankyo Co., Ltd.; Active, not recruiting ➔ Completed; Trial primary completion date: Jul 2018 ➔ Nov 2017
Trial completion • Trial primary completion date • Biosimilar • Oncology • Solid Tumor
December 10, 2019
DS-Screen: Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer population.
(ASCO-GI 2020)
- "Moreover, eligible patients for the clinical trials of DS-1123 or DS-8201, which are FGFR2- or HER2-targeting anti-cancer agent respectively, were screened. This study showed insights into the expression status of FGFR2 and HER2 in GC and CRC as a large-scale prospective analysis. Seven patients who had no standard therapy could access exploratory new drug based on targetable agents through this study. Clinical trial information: 163380."
Clinical • FGFR2 • HER-2 • KRAS • NRAS
1 to 2
Of
2
Go to page
1